This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bottero, D.
Right arrow Articles by Hozbor, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bottero, D.
Right arrow Articles by Hozbor, D.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, November 2007, p. 1490-1498, Vol. 14, No. 11
1071-412X/07/$08.00+0     doi:10.1128/CVI.00177-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pulsed-Field Gel Electrophoresis, Pertactin, Pertussis Toxin S1 Subunit Polymorphisms, and Surfaceome Analysis of Vaccine and Clinical Bordetella pertussis Strains{triangledown}

Daniela Bottero,1 María Emilia Gaillard,1 Matías Fingermann,1 Gabriela Weltman,2 Julieta Fernández,1 Federico Sisti,1 Augusto Graieb,1 Roy Roberts,1 Osvaldo Rico,3 Gustavo Ríos,2 Mabel Regueira,2 Norma Binsztein,2 and Daniela Hozbor1*

Instituto de Bioquímica y Biología Molecular, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calles 47 y 115 (1900), La Plata, Argentina,1 Instituto Carlos G. Malbrán. Av. Velez Sarsfield 563 (1281), Ciudad de Buenos Aires, Argentina,2 Ministerio de Salud de La Nación, Av. 9 de Julio 1925 (C1073ABA), Buenos Aires, Argentina3

Received 20 April 2007/ Returned for modification 1 June 2007/ Accepted 7 August 2007

To add new insight to our previous work on the molecular epidemiology of Bordetella pertussis in Argentina, the prn and ptxS1 gene sequences and pulsed-field gel electrophoresis (PFGE) profiles of 57 clinical isolates obtained during two periods, 1969 to 1989 and 1997 to 2006, were analyzed. Non-vaccine-type ptxS1A was detected in isolates obtained since 1969. From 1989 on, a shift of predominance from the vaccine prn1 type to the nonvaccine prn2 type was observed. This was also reflected in a transition of PFGE group IV to group VI. These results show that nonvaccine B. pertussis strains are currently circulating. To analyze whether the observed genomic divergences between vaccine strains and clinical isolates have functional implications, protection assays using the intranasal mouse challenge model were performed. For such experiments, the clinical isolate B. pertussis 106 was selected as representative of circulating bacteria, since it came from the major group of the PFGE dendrogram (PFGE group VI). Groups of mice were immunized either with diphtheria-tetanus-whole-cell pertussis vaccine (ptxS1B prn1) or a vaccine prepared by us containing B. pertussis 106. Immunized mice were then challenged with a B. pertussis vaccine strain (Tohama, harboring ptxS1B and prn1) or the clinical isolate B. pertussis 106 (ptxS1A prn2). An adequate bacterial-elimination rate was observed only when mice were immunized and challenged with the same kind of strain. For further characterization, comparative proteomic profiling of enriched membrane proteins was done using three vaccine strains and the selected B. pertussis 106 clinical isolate. By matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis, a total of 54 proteins were identified. This methodology allowed us to detect differing proteins among the four strains studied and, in particular, to distinguish the three vaccine strains from each other, as well as the vaccine strains from the clinical isolate. The differing proteins observed have cellular roles associated with amino acid and carbohydrate transport and metabolism. Some of them have been proposed as novel vaccine candidate proteins for other pathogens. Overall, the global strategy described here is presented as a good tool for the development of next-generation acellular vaccines.

* Corresponding author. Mailing address: Instituto de Bioquímica y Biología Molecular, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calles 47 y 115 (1900), La Plata, República Argentina. Phone: 54-221-425-0497, ext. 31. Fax: 54-221-422-6947. E-mail: hozbor{at}biol.unlp.edu.ar

{triangledown} Published ahead of print on 15 August 2007.

Clinical and Vaccine Immunology, November 2007, p. 1490-1498, Vol. 14, No. 11
1071-412X/07/$08.00+0     doi:10.1128/CVI.00177-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Guiso, N., Hozbor, D. (2008). Bordetella pertussis Polymorphism and Pertussis Vaccines. CVI 15: 394-395 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»